16th Jul 2020 21:19
Shield Therapeutics PLC - the pharmaceutical company - Notes the recent publication in Nephrology Dialysis Transplantation of a paper concerning PT20, Shield's iron-based phosphate binder. PT20 has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease. Shield said it has agreed with the US Food & Drug Administration that PT20 requires only one further pivotal phase III study after which regulatory filings for marketing approval would be expected to follow. Shield will first develop a new formulation of PT20 which will allow the phase III study to be carried out and which will be suitable for commercial use. It is anticipated that the formulation work could start in the second half of 2020 which would potentially allow the phase III study to start in 2022, subject to finance being available.
Current stock price: 88.00 pence
Year-to-date change: down 51%
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Shield Thera